Psoriasis and Psoriatic Arthritis in NYC: Treating the Whole Inflammatory Disease, Not Just the Skin

Psoriasis is often described as a skin condition. That framing is incomplete, and it is one of the reasons so many patients in New York City cycle through creams for years without lasting improvement. Psoriasis is a systemic, immune-mediated inflammatory disease. The plaques on your elbows, scalp, or shins are the visible surface of an immune process that also affects your joints, your metabolic health, and your cardiovascular risk.

At Regen Health Physicians, Dr. Ajit Dhaliwal treats psoriasis and psoriatic arthritis the way the evidence suggests it should be treated: as a whole-body inflammatory condition, using a plan that respects conventional dermatology and rheumatology while addressing the metabolic, gut, and lifestyle drivers that standard care often leaves untouched. This guide explains what is actually happening in the immune system, how to tell whether your joints are involved, and what an integrative and regenerative plan looks like in practice.

What Psoriasis Actually Is

In healthy skin, keratinocytes migrate from the basal layer to the surface over roughly 28 days. In a psoriatic plaque, that transit takes 3 to 5 days. The result is the thick, silvery scale patients recognize — skin cells arriving at the surface before they have matured or shed properly.

The acceleration is driven by immune signaling, not by the skin itself. The best-characterized pathway is the IL-23/Th17 axis:

• Dendritic cells in the skin, activated by stress signals, infection, or injury, release IL-23.
• IL-23 drives differentiation and survival of Th17 lymphocytes.
• Th17 cells secrete IL-17A, IL-17F, and IL-22.
• These cytokines drive keratinocyte proliferation, recruit neutrophils, and amplify the loop by inducing more inflammatory signaling.
• Tumor necrosis factor-alpha (TNF-α) reinforces the cycle throughout.

This is not a theoretical model. It is why drugs targeting IL-17 and IL-23 clear plaques so effectively — the biology was validated by the therapeutics. It also explains why the same cytokines show up in joints, entheses (where tendon meets bone), and the vascular wall.

Common Triggers

Psoriasis has a strong genetic component (HLA-C*06:02 is the best-known association), but genes load the gun and environment pulls the trigger. Frequently identified triggers include:

• Streptococcal infection, especially in guttate psoriasis after strep throat
• Physical trauma to skin — the Koebner phenomenon, where plaques appear at sites of injury, scratching, or even tattoo lines
• Psychological stress, mediated through the HPA axis and sympathetic tone
• Medications — lithium, beta-blockers, antimalarials, and abrupt systemic corticosteroid withdrawal
• Smoking and heavy alcohol use, both dose-dependently associated with severity
• Obesity and metabolic dysfunction, discussed below

Psoriatic Arthritis: The Part Patients Miss

Roughly 20 to 30 percent of people with psoriasis develop psoriatic arthritis (PsA). In the large majority, skin disease comes first — often by around a decade — which means a psoriasis diagnosis is an opportunity to screen for joint disease before damage occurs. Erosive joint change in PsA can begin within the first two years of symptoms, and it is not reversible.

Watch for:

• Morning stiffness lasting longer than 30 minutes, improving with movement (inflammatory, not mechanical)
• Dactylitis — a whole finger or toe swollen uniformly, the classic "sausage digit"
• Enthesitis — pain at the Achilles insertion, plantar fascia origin, or lateral elbow that does not behave like ordinary tendinopathy
• Nail changes — pitting, onycholysis, oil-drop discoloration; nail involvement substantially raises PsA risk because the nail bed is anatomically continuous with the distal interphalangeal enthesis
• Inflammatory back pain — night pain, morning stiffness, better with activity, worse with rest
• Asymmetric joint involvement, often distal interphalangeal joints, unlike rheumatoid arthritis

If any of these are present, an evaluation is warranted. Our approach to inflammatory and mechanical joint pain is described on our joint and orthopedic page, and imaging plus rheumatology co-management is part of the plan when PsA is suspected. Regenerative injections do not treat active systemic autoimmune disease — that distinction matters, and we make it explicitly.

Psoriasis Is a Cardiometabolic Disease Too

This is the part most patients are never told. Moderate-to-severe psoriasis is independently associated with:

• Increased risk of myocardial infarction and stroke, over and above traditional risk factors
• Metabolic syndrome, with roughly double the prevalence compared with matched controls
• Type 2 diabetes and insulin resistance
• Non-alcoholic fatty liver disease
• Depression and anxiety, at rates higher than the visible burden alone would predict

The mechanism is shared inflammation. IL-17 and TNF-α promote endothelial dysfunction, insulin resistance in adipose and muscle tissue, and an atherogenic lipid profile. Visceral adipose tissue is itself an inflammatory organ, secreting IL-6, TNF-α, and leptin — which is why weight is not a cosmetic footnote in psoriasis but a disease-modifying variable. Clinical trials have shown that meaningful weight loss in patients with obesity improves psoriasis severity and improves response to systemic therapy.

For that reason, every psoriasis workup at our practice includes cardiometabolic assessment. That intersects directly with the chronic disease program we run for patients with inflammatory and metabolic conditions.

The Workup We Recommend

A thorough evaluation goes well beyond looking at plaques:

Disease characterization

• Body surface area involvement and location (scalp, nails, intertriginous, genital — the last two are underreported and disproportionately affect quality of life)
• Joint and enthesis exam, plus a validated PsA screening questionnaire
• Nail assessment

Inflammatory markers

• hs-CRP and ESR — imperfect in psoriasis but useful for trend
• CBC with differential

Cardiometabolic panel

• Fasting insulin and glucose, HbA1c, HOMA-IR
• Advanced lipids, ideally with ApoB and Lp(a)
• Liver enzymes and, when indicated, hepatic steatosis assessment
• Blood pressure and waist circumference

Nutrient and modifiable factors

• 25-hydroxy vitamin D — deficiency is common and vitamin D signaling regulates keratinocyte differentiation and T-cell behavior
• Omega-3 index
• Ferritin, B12, folate, zinc
• Thyroid panel, given the autoimmune clustering

Gut and infection screening when the history supports it

• Streptococcal serology in guttate presentations
• Assessment for gluten sensitivity or celiac disease, which co-occurs more often than chance
• Symptom-driven evaluation for dysbiosis, since intestinal permeability and the gut-immune axis modulate Th17 activity

Building the Treatment Plan

1. Do Not Abandon Effective Conventional Therapy

For moderate-to-severe psoriasis, biologics targeting IL-17, IL-23, or TNF are the most effective tools available, with many patients achieving near-complete clearance. Integrative medicine done responsibly does not ask patients to refuse them. Our role is to co-manage: optimize everything modifiable so that the medication works better, the dose burden stays lower, and comorbidity risk falls.

For mild disease, topical vitamin D analogues, topical steroids used correctly and intermittently, and phototherapy remain reasonable and evidence-supported first-line options.

2. Nutrition Aimed at the Inflammatory Substrate

The dietary evidence in psoriasis is stronger than skeptics assume, though it is about the pattern rather than any single food:

• Mediterranean-pattern eating is associated with lower psoriasis severity in observational cohorts, likely via polyphenols, monounsaturated fat, and fiber-driven short-chain fatty acid production.
• Weight reduction in patients with obesity improves both severity and treatment response — one of the most reproducible non-drug findings in the literature.
• Omega-3 fatty acids (EPA/DHA) shift eicosanoid production toward less inflammatory mediators; supplementation trials show modest but real benefit, particularly as an adjunct.
• Alcohol reduction matters, both as an independent severity driver and because of interaction with systemic medications.
• Gluten elimination helps a defined subgroup: patients with positive celiac or gliadin serology. It is not a universal recommendation, and testing before eliminating is the correct order of operations.

We do not put patients on elaborate restrictive protocols without a reason. The goal is a sustainable anti-inflammatory pattern plus targeted correction of what testing actually shows.

3. Correcting Metabolic and Nutrient Drivers

Insulin resistance amplifies inflammatory signaling, and psoriasis patients have higher rates of it even at normal weight. Addressing it — through resistance training, protein-adequate nutrition, sleep, and where clinically appropriate pharmacologic support — is genuinely disease-modifying rather than cosmetic. Vitamin D repletion to a sufficient range, omega-3 optimization, and correction of zinc or iron deficiency round out the foundation.

4. Stress Physiology and Sleep

Stress is not a soft variable in psoriasis. Sympathetic activation and dysregulated cortisol rhythm both alter cutaneous immune signaling, and flares after major stressors are well documented. Practically, this means sleep timing and duration, a structured wind-down, and deliberate recovery practice are part of the prescription — not optional extras. The same physiology we address in our longevity and wellness work applies directly here.

5. Peptides and Adjunctive Support — Honestly Framed

Patients ask about peptides constantly, so here is the accurate picture. There are no large randomized trials of peptide therapy for psoriasis. What exists is mechanistic and early-phase data on immune-modulating and tissue-repair peptides, and clinical experience in adjacent inflammatory conditions. Peptides such as thymosin alpha-1 (immune regulation) and anti-inflammatory peptides studied in mucosal and gut inflammation are of legitimate scientific interest, and we discuss them on our peptide therapy page with the same candor we use here: adjunctive, individualized, not a replacement for proven therapy, and only appropriate for selected patients after evaluation.

Anyone promising that peptides will clear moderate-to-severe psoriasis is overselling. We will tell you what is established, what is plausible, and what is unproven.

6. Regenerative Options for Damaged Joints

When PsA has been controlled systemically but a specific joint or enthesis remains symptomatic from structural damage, regenerative approaches may have a role — after, not instead of, immune control. Platelet-rich plasma and related therapies are used for degenerative and tendon-related problems, and our regenerative medicine program for joint, back, and shoulder pain covers what those procedures involve and who is a reasonable candidate. Injecting an actively inflamed autoimmune joint is not appropriate, and sequencing is a clinical judgment we make case by case.

What to Expect on a Realistic Timeline

• Weeks 1–4: Testing complete, conventional therapy optimized or initiated, nutrition and sleep foundation established. Skin changes may be minimal this early.
• Months 2–3: Inflammatory markers and metabolic labs typically begin to move. Plaque thickness and itch often improve before area does.
• Months 3–6: The window where dietary pattern, weight change, and consistent therapy show measurable skin and joint effects. Reassess labs and disease severity.
• Beyond 6 months: Maintenance, flare-trigger identification, and continued cardiometabolic risk reduction. Psoriasis is managed, not cured — but well-managed psoriasis can mean long periods of near-clear skin and stable joints.

Frequently Asked Questions

Is psoriasis contagious? No. It is an immune-mediated process, not an infection of the skin surface.

Can psoriasis be cured? No current therapy cures it. Remission and near-complete clearance are realistic goals for many patients, and comorbidity risk can be meaningfully reduced.

Should I stop my biologic if my skin clears? Not without your prescriber's input. Discontinuation frequently leads to relapse, and in some cases reduced response on restarting. Deprescribing, if appropriate, is a planned decision.

Does psoriasis get worse in winter in New York? Frequently, yes. Reduced UV exposure, low indoor humidity, and lower vitamin D levels all contribute. Seasonal planning — humidification, emollient discipline, vitamin D assessment in autumn — is a small intervention with a real payoff.

What about scalp psoriasis and hair loss? Scalp plaques and the scratching they provoke can cause temporary shedding. It is usually reversible once inflammation is controlled, though it can coexist with other causes of thinning. Our hair restoration program evaluates scalp inflammation as part of any hair loss workup.

The Bottom Line

Treating psoriasis as skin-deep leaves most of the disease untreated. The same cytokines producing your plaques are acting on your joints, your blood vessels, and your metabolism. A complete plan uses the most effective therapies available for the skin while systematically addressing weight, insulin sensitivity, nutrient status, sleep, stress, and gut health — and screens deliberately for psoriatic arthritis, where early detection prevents permanent damage.

Dr. Ajit Dhaliwal sees patients in New York City and Salt Lake City. If you have psoriasis and have never had a cardiometabolic evaluation or a formal joint screen, that is the gap worth closing. Book a consultation or read more about our approach and philosophy.

---

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Psoriasis and psoriatic arthritis require individualized evaluation by a licensed physician. Do not start, stop, or change any medication — including biologics, systemic therapies, or supplements — without consulting your treating clinician. Peptide therapies discussed here are not FDA-approved treatments for psoriasis.